ACELYRIN’s Merger with Alumis

Fenwick & West advised ACELYRIN, INC. on the transaction, and Cooley advised Alumis Inc. ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Paragraf’s Acquisition of Cardea Bio

Fenwick advised Paragraf on the deal. Paragraf, a producer graphene electronics using transfer-free graphene and standard semiconductor processes, announced its acquisition of Cardea Bio, a producer of...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here